Doximity's Stock Takes a Hit as AI Investments Impact Outlook: Freedom Capital Downgrades to Hold

Well, folks, it looks like Doximity (DOCS), that popular California-based digital platform where countless physicians connect, has hit a bit of a snag on Wall Street. Just yesterday, on September 8, 2026, Freedom Capital Markets decided to pull back its recommendation, downgrading Doximity's stock from a 'Buy' to a more cautious 'Hold.' It's certainly a move that catches the eye, especially for those invested in the bustling healthcare tech space.

So, what's behind this shift in sentiment? The core reason, it seems, lies squarely with Doximity's recent adjustment to its fiscal year 2027 adjusted EBITDA outlook. The company decided to trim its guidance, now projecting between $309 million and $329 million. That's a noticeable step down from their earlier, more optimistic forecast of $323 million to $335 million. Interestingly, this revised range now sits just below the Bloomberg consensus of $328.9 million. And the culprit? According to Doximity, it’s all about funneling more funds into their burgeoning AI initiatives. While AI is certainly the buzzword of the moment, these increased investments are, at least for now, eating into their projected near-term profitability, creating a bit of a short-term squeeze.

Gene Mannheimer, the analyst over at Freedom Capital Markets, didn't mince words when explaining the rationale behind the downgrade. He painted a picture of Doximity as 'somewhat of a 'fallen star,'' acknowledging its inherent strengths. After all, it's a 'sticky, high-margin, physician-network cash generator' – a pretty impressive profile, by any measure. But here's the rub: Mannheimer believes the shares just aren't 'priced cheaply enough to defend buying the stock until AI monetization shows up more visibly in the numbers.' In other words, while the long-term AI play might be promising, the immediate financial impact isn't yet translating into a compelling reason to buy at current valuations. The market, it seems, wants to see tangible returns, not just promises of future innovation.

And to further underscore this cautious stance, Freedom Capital Markets also cut its price target for Doximity. What was once a hopeful $27 target is now set at a more modest $24. It’s a clear signal that the investment landscape for Doximity has shifted, at least for the time being, as the company navigates the expense of integrating cutting-edge AI into its valuable platform.